Dexmedetomidine Infusion in Either Total Intravenous Anesthesia or Inhalational Anesthesia to Improve Surgical Field Visibility in Endoscopic Sinus Surgery

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06866145

Enrollment

Registered

2025-03-10

Start date

2024-05-01

Completion date

2025-07-01

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinosinusitis

Keywords

endoscopic sinus surgery , dexmedetomidine, surgical field visibility

Brief summary

Dexmedetomidine Infusion in either Total Intravenous Anesthesia or Inhalational Anesthesia to Improve Surgical Field Visibility in Endoscopic Sinus Surgery

Detailed description

the study was prospective randomized single blinded study

Interventions

PROCEDUREfunctional endoscopic sinus surgery

sinus surgery

DRUGDexmedetomidine

precedex

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Masking description

surgeon

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists (ASA) class I and II patients undergoing endoscopic sinus surgery in the age group from 18-50 years.

Exclusion criteria

* History of allergy to medications used in the study, refusal of patients to participate, hepatic or renal dysfunction, chronic pain condition, psychological and neurological disorders

Design outcomes

Primary

Measure	Time frame	Description
Surgical field visibility	intraoperative	Surgical field visibility assessed every 15 minutes based on Boezaart scale from 0 to 5 as 0 is the worst score and 5 is the best

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026